Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Top Analyst Reports for Alibaba, AbbVie & Exxon Mobil

Published 08/11/2021, 03:24 AM
Updated 07/09/2023, 06:31 AM

Wednesday, August 11, 2021

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alibaba (NYSE:BABA) Group Holding Limited (BABA), AbbVie Inc (NYSE:ABBV). (ABBV), and Exxon Mobil Corporation (NYSE:XOM) (XOM). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Alibaba have suffered lately, as have other Chinese Tech stocks, in response to the Chinese authorities' regulatory crackdown. While these near-term headwinds are all too real, the company remains well positioned for long-term investors.

Its strengthening cloud business continues to drive its performance on the back of an expanding customer base. Rising competition from domestic as well as foreign e-commerce companies, however, poses a serious risk. Regulatory concerns and higher costs associated with new initiatives remain major headwinds.

(You can read the full research report on Alibaba here >>>)

AbbVie shares have gained +12.2% over the last six months against the Zacks Large-Cap Pharmaceuticals industry’s gain of +16.1%, however, it’s Q2 earnings were in line with estimates while sales beat the same. The Zacks analyst believes that AbbVie’s flagship product, Humira, continues to drive revenues

It has an impressive late-stage pipeline with several early/mid-stage candidates that have immense potential. Skyrizi and Rinvoq, two of its new immunology drugs, have been performing beyond expectations. Sales erosion due to direct biosimilar competition to Humira in international markets is a big headwind though. The uncertainty regarding FDA decision on label expansion filings of Rinvoq due to controversies surrounding JAK inhibitors drugs is another concern.

(You can read the full research report on AbbVie here >>>)

Shares of Exxon Mobil have gained +44.8% in the year to date period against the Zacks Integrated International Oil industry’s gain of +30.1%. The Zacks analyst believes that major discoveries in the Stabroek Block have enhanced prospects for ExxonMobil's upstream businesses.

The company recently reported strong second-quarter results, on the back of improved realized oil and natural gas prices as well as higher chemical margins. Its downstream business, however, suffered due to planned maintenance and unfavorable foreign exchange. Lower margins on the back of weak refining business continue to hurt the integrated energy player’s downstream operations in the United States.

(You can read the full research report on Exxon Mobil here >>>)

Other noteworthy reports we are featuring today include Sony (NYSE:SONY) Group Corporation (SONY), American Tower (NYSE:AMT) Corporation (AMT) and Caterpillar Inc (NYSE:CAT). (CAT).

Sheraz Mian

Director of Research

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>


Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

American Tower Corporation (AMT): Free Stock Analysis Report

Caterpillar Inc. (CAT): Free Stock Analysis Report

Exxon Mobil Corporation (XOM): Free Stock Analysis Report

AbbVie Inc. (ABBV): Free Stock Analysis Report

Alibaba Group Holding Limited (BABA): Free Stock Analysis Report

Sony Corporation (SONY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.